Inovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation

Jul 06, 2017

Inovio dMAb® product induces complete protection against lethal challenge with influenza A & B viruses in published preclinical study

PLYMOUTH MEETING, Pa., July 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection from a lethal challenge with multiple viruses from both influenza A and B types in a preclinical study. Results of this study in mice were published in the journal npj Vaccines in an article entitled “DNA Inoculation of Synthetic Cross-Reactive Antibodies Protects Against Lethal Influenza A and B Infections,” authored by Inovio and its collaborators.

Following on previously reported similar data from its dMAb® products for HIV, dengue, and Chikungunya, this study further validates the ability of Inovio’s dMAb technology platform to use encoded DNA plasmids to enable in vivo production of monoclonal antibodies and induce protective immune responses. The goal for this platform is to rapidly generate therapeutic monoclonal antibodies directly in the recipients. Such benefits are complementary to Inovio’s antigen-generating platform in terms of immune mechanism and short response times, and advantages that overcome conventional monoclonal antibodies’ long development lead times and complex manufacturing processes and costs.

Inovio’s dMAb products deliver DNA sequences that encode and directly result in the in vivo production of protective antibodies, unlike its DNA vaccines which attempt to incite the production of antibodies through the immune system. In the case of influenza and other infectious disease, a dMAb product may provide immediate and short term protection while a DNA vaccine may provide long term immune memory and protection. Both products can be encoded to provide cross-strain protection. Inovio’s influenza dMAb product was designed to provide cross-strain protection across two major sub-types of influenza, A and B. This approach would bypass the burdensome design and manufacturing approach for conventional monoclonal antibodies that make them less ideal for pandemic situations and would be desirable in their potential ability to offer prevention against unexpected changes of seasonal influenza strains.

“The annual flu vaccine matching process is not a perfect science, therefore in some flu seasons the vaccine available in the fall is much less effective,” said Dr. David B. Weiner, Executive Vice President and Director of the Vaccine and Immune Therapy Center at The Wistar Institute and the lead author of the study. “Flu occasionally can dramatically shift strains, resulting in a pandemic strain that requires a new strategy for developing a vaccine and leaving populations at risk of major health consequences. Furthermore, some vulnerable people may not respond well to vaccines and this new approach that is simple, rapid and can broadly protect against influenza would be a major step forward,” said Dr. Weiner, who is also a member of the Inovio board and a scientific adviser.

Dr. J. Joseph Kim, Inovio's President and CEO, said, “Inovio’s dMAb products represent a new class of products we are developing to treat cancers and infectious diseases using our potent platform. Funded by over $60 million in grants from DARPA, NIH, and the Gates Foundation, these dMAb products can extend the medical benefits that marketed monoclonal antibodies have already achieved and potentially address diseases that conventional monoclonal antibodies cannot. With respect to influenza, our dMAb product offers a new game-changing model to address seasonal and pandemic influenza with a single dose. We look forward to advancing the first dMAb product – our therapeutic Ebola product funded by DARPA – into human testing in 2018.”

While Inovio is advancing its dMAb technology against infectious disease targets, this platform is applicable beyond these diseases. Conventional monoclonal antibodies are costly and time consuming to develop, produce and study. They are manufactured outside the body, typically requiring costly large-scale manufacturing facility development and laborious production. Inovio’s DNA-based monoclonal antibodies have the potential to overcome these limitations by virtue of their simplified design, rapidity of development, product stability, ease of manufacturing and deployablity, and cost effectiveness, thereby providing potential new avenues for treating a range of diseases.

This published study was supported by grants from DARPA and the National Institutes of Health for a collaborative study that, in addition to Inovio, includes scientists from The Wistar Institute and MedImmune, AstraZeneca’s global biologics research and development arm.

About Inovio’s DNA-based Monoclonal Antibody Platform

The significant advancement seen in Inovio’s dMAb technologies is that the optimized genes for a desired monoclonal antibody is encoded in a DNA plasmid, which is produced using very cost effective and highly scalable fermentation techniques. These plasmids are delivered directly into cells of the body using electroporation and the encoded monoclonal antibody is then directly produced by these cells. Previously published studies show that a single administration of a highly optimized DNA-based monoclonal antibody targeting HIV virus produced a high level of expression of the antibody in the bloodstream of mice; Inovio similarly reported data showing that dMAb products against Ebola, chikungunya and dengue protected animals against lethal challenge. Inovio’s Ebola dMAb® product is being developed under a grant from the Defense Advanced Research projects Agency (DARPA).

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and dMAb® products, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including its dMAb® technology, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, our Form 10-Q for the quarter ended March 31, 2017, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

In addition, the forward-looking statements included in this press release represent Inovio’s views as of the date hereof. Inovio anticipates that subsequent events and developments may cause its views to change. However, while Inovio may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing Inovio’s views as of any date subsequent to the date of this release.

CONTACTS:
Investors/Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

Primary Logo

Source: Inovio Pharmaceuticals

Stay informed:

Email Address *


*Required Fields